

REMARKS

Prior to this amendment, claims 1-13, 15, 16, 18, 19, 22, and 26-29 were pending. Applicants have cancelled claim 18 and claim 19. Thus, claims 1-13, 15, 16, 22, and 26-29 are currently pending and under consideration.

Applicants have indicated claim 16 as being amended (to recite "in need of such a treatment"). In their June 3, 2005 response, applicants had inadvertently indicated claim 16 as being "original" instead of "currently amended".

Applicants have added claim 30 directed to species of the claimed invention. Support for this amendment may be found throughout the specification as originally filed and in Tables 9-12 (pages 167-168, pages 181-182, pages 194-195, and pages 208-209).

None of these amendments add new matter.

All of these amendments and claim cancellations are specifically without prejudice to applicants seeking patents for the subject matter of the cancelled claims or to the non-elected subject matter.

Rejections under 35 U.S.C. § 112, first paragraph:

Claim 18 and claim 19 stands rejected under 35 U.S.C. § 112, first paragraph, "as failing to comply with the enablement requirement." Applicants have cancelled claim 18 and claim 19 thus obviating these rejections. Accordingly, applicants request that the Examiner withdraw these 112, first paragraph rejections.

For all the above reasons, applicants request that the Examiner withdraw these 112, first paragraph rejections.

CONCLUSION

Applicants request that the Examiner enter the above amendments, consider the foregoing remarks, and allow the pending claims to issue. If the Examiner believes that a telephone call would expedite prosecution, the Examiner is invited to contact the undersigned at any time.

Respectfully submitted,



Lisa A. Dixon

Registration No: 40,995

Attorney for Applicants

VERTEX PHARMACEUTICALS INCORPORATED

130 Waverly Street

Cambridge, Massachusetts 02130-4646

Tel: (617) 444-6396

Fax: (617) 444-6483